Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer : Episode 1

Opinion

Video

June 1, 2024

Navigating BCG Shortages in NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Navigating BCG Shortages in NMIBC

EP: 2.The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

EP: 3.Efficacy and Safety Data from SunRISe-1

EP: 4.Overview of the QUILT Trial in BCG-Unresponsive NMIBC

EP: 5.Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

EP: 6.Adverse Effect Management and the Role of Immunotherapy in NMIBC

EP: 7.Selecting Optimal Treatment in BCG-Unresponsive NMIBC

EP: 8.Patient Monitoring Strategies in BCG-Unresponsive NMIBC

EP: 9.Promising Developments in NMIBC

EP: 10.Key Takeaways on the Evolving NMIBC Treatment Landscape

Related Videos

Laura Davis, MD, on link between microplastics and bladder cancer

Laura Davis, MD, on link between microplastics and bladder cancer

Rebecca A. Campbell, MD, answers a question during a Zoom video interview

Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature

Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC

Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC

Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview

Expert discusses the NMIBC trials landscape

John Gore, MD, on bladder preservation in muscle–invasive bladder cancer

John Gore, MD, on bladder preservation in muscle–invasive bladder cancer

Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC

Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC

Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview

Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy

Joseph Jacob, MD, on the durability of TAR-200 in NMIBC

Joseph Jacob, MD, on the durability of TAR-200 in NMIBC

Study data point to gender disparities in oncology research citations

Study data point to gender disparities in oncology research citations

Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC

Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC

Related Content

Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

medical depiction of bladder cancer

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Human urinary bladder | Image Credit: © magicmine - stock.adobe.com

May 9th 2025

Durvalumab plus BCG significantly improves DFS in NMIBC

Benjamin P. Saylor Hannah Clarke

The data are to be presented at an upcoming medical conference.

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

FDA to host advisory committee meeting on UGN-102 for NMIBC

May 7th 2025

FDA to host advisory committee meeting on UGN-102 for NMIBC

The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

May 5th 2025

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

The sBLA for NAI was submitted to the FDA in March 2025.

Related Content

Bladder Cancer Viewpoints Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer Michigan Institute of Urology

|

|

Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

|

Michigan Institute of Urology

Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

medical depiction of bladder cancer

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Human urinary bladder | Image Credit: © magicmine - stock.adobe.com

May 9th 2025

Durvalumab plus BCG significantly improves DFS in NMIBC

Benjamin P. Saylor Hannah Clarke

The data are to be presented at an upcoming medical conference.

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

FDA to host advisory committee meeting on UGN-102 for NMIBC

May 7th 2025

FDA to host advisory committee meeting on UGN-102 for NMIBC

The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

May 5th 2025

FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

The sBLA for NAI was submitted to the FDA in March 2025.

Recent Content

Blurred interior of hospital - abstract medical background. | Image Credit: © jakkapan - stock.adobe.com

Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy

Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Published data support safety, efficacy of vaginal insert for SUI

Published data support safety, efficacy of vaginal insert for SUI

Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer

Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer

View More Recent Content

Terms and Conditions

Do not sell my Personnal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.